William Lis steps down as CEO; Ronald Martell appointed President and CEO; Lis becomes Chairperson

Jasper Therapeutics, Inc.

William Lis terminates employment as CEO effective March 15, 2022; remains as Class III director and non-employee Chairperson for 12-month term.
As Chairperson, Lis receives $250,000 annual fee; after board service, consulting at $12,250/month through later of 12 months or March 15, 2024.
Lis will be granted option to purchase 100,000 shares of common stock, vesting monthly over 12 months commencing March 15, 2022.
Prior employment agreement and severance plan terminated; if terminated without Cause, Lis receives continued annual fee and full option vesting.
Ronald Martell appointed as President and CEO; specific compensation terms for Martell not disclosed in this filing.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William Lis

Chairperson of the Board

JSPR · Jasper Therapeutics, Inc.

Effective: 2022-03-15
Filed: March 11, 2022, 6:59 PM ET

Mr. Lis will continue serving as a Class III director of the Company and will commence serving as a non-employee Chairperson of the Company’s Board of Directors (the “Board”).

Appointed

Ronald Martell

President and Chief Executive Officer

JSPR · Jasper Therapeutics, Inc.

Effective: 2022-03-07
Filed: March 11, 2022, 6:59 PM ET

On March 7, 2022, in connection with the appointment of Ronald Martell as the President and Chief Executive Officer of Jasper Therapeutics, Inc. (the “Company”),

Departed

William Lis

Chief Executive Officer

JSPR · Jasper Therapeutics, Inc.

Effective: 2022-03-15
Successor: Ronald Martell
Filed: March 11, 2022, 6:59 PM ET

Mr. Lis’ employment with the Company will terminate as of March 15, 2022, at which time, Mr. Lis will continue serving as a Class III director of the Company and will commence serving as a non-employee Chairperson of the Company’s Board of Directors (the “Board”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

William Lis was appointed as Chairperson of the Board at Jasper Therapeutics, Inc..

Action: commenced serving
Role: Chairperson of the Board

Exact text from the filing

Mr. Lis will continue serving as a Class III director of the Company and will commence serving as a non-employee Chairperson of the Company’s Board of Directors (the “Board”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ronald Martell was appointed as President and Chief Executive Officer at Jasper Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On March 7, 2022, in connection with the appointment of Ronald Martell as the President and Chief Executive Officer of Jasper Therapeutics, Inc. (the “Company”),

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

William Lis was terminated as Chief Executive Officer at Jasper Therapeutics, Inc..

Action: terminated
Role: Chief Executive Officer

Exact text from the filing

Mr. Lis’ employment with the Company will terminate as of March 15, 2022, at which time, Mr. Lis will continue serving as a Class III director of the Company and will commence serving as a non-employee Chairperson of the Company’s Board of Directors (the “Board”).

View on SEC.gov

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-011854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.